Diagnosis
Lichen planus
Chronic inflammation of the skin or mucous membranes causing lichenificating lesions.
Etiology
Cause [aue][rd9]
Precise cause is unknown
A possible explanation is an abnormal immunological reaction to different exogenous agents such as viruses, drugs, or contact allergens [aue]
Drug-induced lichen planus (lichenoid drug eruption) can resemble idiopathic lichen planus
Pathophysiology [aue][rd9]
Cytotoxic CD8 T cells recognize an unknown antigen causing destruction of keratinocytes
Complications [iom][aue]
Scarring
Stricture
Post-inflammatory hyperpigmentation
Onychodystrophy
Malignant transformation into squamous cell carcinoma
Secondary infection
Epidemiology
Incidence per 100.000 [iom][35c][f1t][uru]
Prevalence per 100.000 [iom][35c][f1t][uru]
Symptoms & findings
Symptoms
Onycholysis, Pruritus, Xeroderma
Clinical findings
None listed.
Anamneses
None listed.
Localized findings
Approach
Clinical diagnosis: [iom]
Skin lesions: Itchy, violaceous papules/plaques
Location: Wrists, lower back, ankles, oral mucosa (rarely affects the vulva, the vagina, the pharynx, the larynx, and the oesophagus)
Wickham’s stria (white lines) are pathognomonic of the condition [35c]
Biopsy
Treatment
The condition is self-limited and generally lasts 6–24 months [35c][aue]
Symptomatic treatment:
Avoid: spicy/acidic food, alcohol, tobacco
Antihistamine (pruritus)
Steroid cream twice daily for 2 to 4 weeks
Intralesional steroid injections (triamcinolone 5 to 10 mg/mL)
First-line therapy:
Oral corticosteroids (prednisone 30 to 60 mg) tapered over 2 to 6 weeks
Second-line therapy: [aue]
Metronidazole (500 mg twice daily for 3 to 8 weeks)
Sulfasalazine (500 mg twice daily increased until 2.5 grams daily, for 3 to 6 weeks)
Isotretinoin (10 mg twice daily for 2 months)
Acitretin (30 mg daily for 8 weeks)
PUVA, UVB
Topical calcineurin inhibitors
Methotrexate (15 mg per week for adults, 0.25 mg/kg per week for children)
Third line therapy: Trimethoprim-sulfamethoxazole, griseofulvin, terbinafine, antimalarials, tetracyclines, ciclosporin, mycophenolate mofetil, azathioprine, etanercept, adalimumab, or low-molecular-weight heparin [aue]
Differential diagnoses
Candidiasis, Cutaneous T-cell lymphoma, Drug side effects, Eczema, Graft-versus-host disease, Lichenoid keratosis, Lichen sclerosus, Paget's disease, Parapsoriasis, Pityriasis lichenoides, Pityriasis rosea, Pityriasis rubra pilaris, Pityriasis versicolor, Psoriasis, Squamous cell carcinoma, Syphilis, Systemic lupus erythematosus, Tinea corporis
References
[1] Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2024 Oct 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/
[2] [Clinical Dermatology 4.th Edition by Weller, Hunter, Savin and Dahl]
[3] Halonen P, Jakobsson M, Heikinheimo O, Gissler M, Pukkala E. Incidence of Lichen Planus and Subsequent Mortality in Finnish Women. Acta Derm Venereol. 2020 Oct 28;100(17):adv00303.
[4] Pannell RS, Fleming DM, Cross KW. The incidence of molluscum contagiosum, scabies and lichen planus. Epidemiol Infect. 2005 Dec;133(6):985-91.
[5] Nagao T, Ikeda N, Fukano H, Hashimoto S, Shimozato K, Warnakulasuriya S. Incidence rates for oral leukoplakia and lichen planus in a Japanese population. J Oral Pathol Med. 2005 Oct;34(9):532-9.
[6] Schruf E, Biermann MH, Jacob J, Häckl D, Reinhardt M, Hertl M, Wohlrab J. Lichen planus in Germany - epidemiology, treatment, and comorbidity. A retrospective claims data analysis. J Dtsch Dermatol Ges. 2022 Aug;20(8):1101-1110.
[7] Carbone M, Arduino PG, Carrozzo M, Gandolfo S, Argiolas MR, Bertolusso G, Conrotto D, Pentenero M, Broccoletti R. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Dis. 2009 Apr;15(3):235-43.